China Universal Asset Management Co. Ltd. Buys Shares of 15,396 Biohaven Ltd. (NYSE:BHVN)

China Universal Asset Management Co. Ltd. bought a new position in Biohaven Ltd. (NYSE:BHVN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 15,396 shares of the company's stock, valued at approximately $575,000.

A number of other large investors have also recently added to or reduced their stakes in BHVN. nVerses Capital LLC bought a new position in shares of Biohaven in the third quarter worth about $50,000. Values First Advisors Inc. bought a new position in Biohaven in the 3rd quarter worth approximately $78,000. US Bancorp DE increased its position in Biohaven by 57.1% in the 3rd quarter. US Bancorp DE now owns 2,173 shares of the company's stock worth $109,000 after buying an additional 790 shares during the period. KBC Group NV lifted its holdings in shares of Biohaven by 24.5% during the third quarter. KBC Group NV now owns 2,250 shares of the company's stock worth $112,000 after buying an additional 443 shares during the last quarter. Finally, Venturi Wealth Management LLC boosted its position in shares of Biohaven by 19.1% in the third quarter. Venturi Wealth Management LLC now owns 3,117 shares of the company's stock valued at $156,000 after acquiring an additional 500 shares during the period. Institutional investors own 88.78% of the company's stock.

Biohaven Stock Down 0.6 %

NYSE:BHVN traded down $0.24 during trading hours on Thursday, reaching $38.90. The company had a trading volume of 509,549 shares, compared to its average volume of 900,865. The firm has a market capitalization of $3.93 billion, a PE ratio of -4.16 and a beta of 1.28. The stock has a 50-day moving average of $39.05 and a two-hundred day moving average of $42.56. Biohaven Ltd. has a one year low of $26.80 and a one year high of $62.21.

Biohaven (NYSE:BHVN - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.03). As a group, sell-side analysts expect that Biohaven Ltd. will post -8.85 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on BHVN shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Biohaven in a research note on Tuesday, December 17th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 price objective (up previously from $58.00) on shares of Biohaven in a research report on Wednesday, December 4th. TD Cowen increased their target price on shares of Biohaven from $55.00 to $75.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. Finally, HC Wainwright restated a "buy" rating and set a $59.00 price target on shares of Biohaven in a research note on Tuesday, December 17th. Thirteen analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $63.00.

Insider Transactions at Biohaven

In other Biohaven news, Director John W. Childs purchased 29,000 shares of the business's stock in a transaction that occurred on Monday, December 30th. The stock was acquired at an average cost of $35.94 per share, with a total value of $1,042,260.00. Following the completion of the acquisition, the director now directly owns 2,368,741 shares of the company's stock, valued at $85,132,551.54. This represents a 1.24 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 16.00% of the company's stock.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.